TVI-Brain-1
Phase 3Biologic
TVI-Brain-1 is one of 55 biologic programs targeting Glioblastoma Multiforme. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
60 competitors in Glioblastoma Multiforme
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Avastin
RochePhase 3
Gilenya
NovartisApproved
Istodax
TevaApproved
Lynparza
AstraZenecaApproved
Niacor
AbbVieApproved
Bayer Aspirin
BayerApproved
Keppra
UCBApproved
Cialis
Eli LillyApproved
Talzenna
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Glioblastoma Multiforme1 trial
Glioma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TVI-Brain-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- TTVAX Biomedical